Telesis Bio Past Earnings Performance
Past criteria checks 0/6
Telesis Bio's earnings have been declining at an average annual rate of -20%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 27.6% per year.
Key information
-20.0%
Earnings growth rate
22.2%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 27.6% |
| Return on equity | -1,163.5% |
| Net Margin | -278.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More
Apr 17
Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance
Aug 09Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space
Jan 06Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021
Sep 24Revenue & Expenses Breakdown
How Telesis Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 17 | -47 | 26 | 13 |
| 30 Jun 24 | 20 | -51 | 31 | 14 |
| 31 Mar 24 | 25 | -47 | 32 | 15 |
| 31 Dec 23 | 28 | -49 | 35 | 17 |
| 30 Sep 23 | 25 | -37 | 36 | 16 |
| 30 Jun 23 | 28 | -39 | 36 | 19 |
| 31 Mar 23 | 26 | -46 | 38 | 22 |
| 31 Dec 22 | 27 | -48 | 39 | 23 |
| 30 Sep 22 | 21 | -53 | 36 | 24 |
| 30 Jun 22 | 17 | -50 | 34 | 22 |
| 31 Mar 22 | 14 | -45 | 30 | 18 |
| 31 Dec 21 | 11 | -39 | 25 | 14 |
| 30 Sep 21 | 10 | -32 | 21 | 12 |
| 30 Jun 21 | 9 | -27 | 17 | 11 |
| 31 Mar 21 | 8 | -22 | 13 | 10 |
| 31 Dec 20 | 7 | -18 | 11 | 9 |
| 31 Dec 19 | 6 | -10 | 7 | 4 |
Quality Earnings: TBIO is currently unprofitable.
Growing Profit Margin: TBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TBIO is unprofitable, and losses have increased over the past 5 years at a rate of 20% per year.
Accelerating Growth: Unable to compare TBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TBIO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: TBIO has a negative Return on Equity (-1163.47%), as it is currently unprofitable.